UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 


 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) January 5, 2017

 

CANTEL MEDICAL CORP.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-31337

 

22-1760285

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(IRS Identification
Number)

 

150 Clove Road, Little Falls, New Jersey

 

07424

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (973) 890-7220

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07  Submission of Matters to a Vote of Security Holders.

 

At the 2016 Annual Meeting, held on January 5, 2017, three proposals were voted on by the Company’s stockholders.  The proposals are described in detail in the Company’s definitive proxy statement filed on November 28, 2016 (the “Proxy Statement”) in connection with the 2016 Annual Meeting and summarized below.

 

A final voting report was produced by Broadridge Financial Solutions, Inc., the independent inspector of election for the 2016 Annual Meeting, certifying the following results on the three proposals:

 

Proposal 1                                                The stockholders elected all nine director nominees to serve as members of the Company’s board of directors until the Company’s 2017 Annual Meeting of Stockholders.

 

Name

 

For

 

Withheld

 

Abstain

 

Broker
Non-Votes

Alan R. Batkin

 

36,079,638

 

718,533

 

17,371

 

2,609,004

Ann E. Berman

 

36,559,252

 

239,236

 

17,054

 

2,609,004

Charles M. Diker

 

35,380,416

 

1,416,432

 

18,694

 

2,609,004

Mark N. Diker

 

35,535,474

 

1,262,331

 

17,737

 

2,609,004

Anthony B. Evnin

 

36,446,941

 

343,714

 

24,887

 

2,609,004

Laura L. Forese

 

36,556,963

 

241,138

 

17,441

 

2,609,004

George L. Fotiades

 

36,539,534

 

250,734

 

25,274

 

2,609,004

Jorgen B. Hansen

 

36,187,104

 

610,997

 

17,441

 

2,609,004

Ronnie Myers

 

36,563,596

 

234,505

 

17,441

 

2,609,004

 

Proposal 2                                            The stockholders approved, on an advisory basis, the compensation of the Company’s Named Executive Officers.

 

For

 

Against

 

Abstain

 

Broker
Non-Votes

35,638,918

 

1,149,828

 

26,796

 

2,609,004

 

Proposal 3                                            The stockholders ratified the appointment of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending July 31, 2017.

 

For

 

Against

 

Abstain

 

Broker
Non-Votes

38,745,700

 

668,327

 

10,519

 

0

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

CANTEL MEDICAL CORP.

 

(Registrant)

 

 

 

 

 

 

 

By:

/s/ Jorgen B. Hansen

 

 

Jorgen B. Hansen

 

 

President and Chief Executive Officer

 

 

 

Date: January 10, 2017

 

 

 

3